Close
Clinical Trials
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk
Cancer Type
Breast
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani, MD, DSc
For more information about this study
View DetailsAbout This Study
A Study of imlunestrant vs physician’s choice endocrine therapy as adjuvant treatment after 2 to 5 years of standard adjuvant endocrine therapy for patients with ER+, HER2- early breast cancer with an increased risk of recurrence